All In Biotech

Drug Trial Radar · NCT02772068

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

Hemodynamic Response to Exercise in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients After Upregulation of SERCA2a

Last checked: Nov 19, 2026Latest source record: Jun 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Sep 15, 2015

Primary completion

Dec 1, 2018

Study completion Dec 1, 2018

Sponsor

Lead sponsor
Benjamin LevineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
May 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Heart failure with preserved ejection fraction or HFpEF, represents nearly 50% of all heart failure cases and is particularly common in the elderly. The disease has no current treatment options. Symptoms typically occur during exertion or exercise and is likely the result of increased cardiac and pulmonary congestion as a result of impaired diastolic function. Istaroxime is a novel activator of SERCA2a, an important regulator of calcium uptake within the myocyte. We will test the hypothesis that Istaroxime will improve diastolic function during exercise in HFpEF patients which in turn will reduce cardiac and pulmonary congestion.

Conditions

  • Heart Failure, Congestive

Interventions

  • IstaroximeDrug

    Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.

  • ExerciseOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in cardiac filling pressures (pulmonary capillary wedge pressure) during exercise with IstaroximeTime frame: Immediate; 90 minutes after infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Institute for Exercise and Environmental Medicine

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.